Table 1.
Patient characteristics from three phase II trials of presurgical VEGF targeted therapy from which the primary tissues were used for analysis in this study
| Presurgical drug | Sunitinib (EudraCT 2006-006491-38) a |
Sunitinib (NCT00715442) a |
Bevacizumab (NCT00113217) a |
|---|---|---|---|
| Number of patients | 12 | 9 | 29 |
| age | 56 (range:39-75) |
61 (range: 49-76) |
61 (range: 41-74) |
| Gender -male -female |
10 2 |
6 3 |
22 7 |
| MSKCC risk score -intermediate -poor |
11 1 |
6 3 |
25 4 |
| Number of metastatic sites 1 2 3 4 |
2 5 5 |
5 3 1 |
2 17 6 4 |
| Metastatic sites Lung Bone Lymph node Liver other |
10 5 4 3 5 |
9 1 4 |
25 7 17 2 19 |
| Median reduction primary tumor (percent longest diameter) |
11% (range: +2.2 - −36%) |
5% (range 0- −10%) |
1% (range +11- −33%) |
| Progression free survival (median and range) |
8.5 months (range 4-48 months) |
14 months (range 3-40 months) |
5.5 months (range 1-24 months) |
| Overall survival (median and range) |
20.5 months (range 5-48 months) |
35 months (range 6-40 months) |
18.6 (range 3-40 months) |
a
clinical trial identifier (clinicaltrials.gov)